Literature DB >> 18088246

Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma.

C-H Hung1, C-H Chen, C-M Lee, C-M Wu, T-H Hu, J-H Wang, Y-H Yen, S-N Lu.   

Abstract

NS5A and E2 proteins of the hepatitis C virus (HCV) have the potential to repress protein kinase R (PKR) that exerts a tumour suppressor function. We investigated the relationship between amino acid variations in the NS5A-PKR-binding domain and E2-PKR-eIF2alpha phosphorylation homology domain (PePHD) region and the development of hepatocellular carcinoma (HCC) in chronic HCV-1b patients. In a cross-sectional, hospital-based setting, we compared the amino acid sequences of NS5A-PKR-binding domain and E2-PePHD in the sera of 104 chronic hepatitis, 44 cirrhosis and 96 HCC patients. The nucleotide sequences were inferred by direct sequencing of the amplified HCV products and deduced amino acid were compared with the sequence of HCV-J. By univariate analysis, old age, lower viral load, fewer amino acid substitutions in the NS5A-PKR-binding domain (codons 2209-2274) and the interferon sensitivity-determining region (ISDR; codons 2209-2248), and wild-type amino acid at codon 2209 and codon 2240 was significantly correlated with HCC, whereas substitutions in the E2-PePHD was not. Patients with a mutated-type (> or = 4) NS5A-ISDR had a lower prevalence of HCC than those with intermediate or wild type (P < 0.05). Based on stepwise logistic regression analysis, age [odds ratio (OR): 1.132, P < 0.001], viral load (OR: 0.305, P < 0.001) and mutated-type ISDR (OR: 0.137, P = 0.001) were independently associated with HCC. In conclusion, NS5A-ISDR variations may play an important role in the development of HCV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18088246     DOI: 10.1111/j.1365-2893.2007.00892.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  11 in total

1.  Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection.

Authors:  Chao-Hung Hung; Jing-Houng Wang; Tsung-Hui Hu; Chien-Hung Chen; Kuo-Chin Chang; Yi-Hao Yen; Yuan-Hung Kuo; Ming-Chao Tsai; Sheng-Nan Lu; Chuan-Mo Lee
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.

Authors:  Yusuke Funaoka; Naoya Sakamoto; Goki Suda; Yasuhiro Itsui; Mina Nakagawa; Sei Kakinuma; Takako Watanabe; Kako Mishima; Mayumi Ueyama; Izumi Onozuka; Sayuri Nitta; Akiko Kitazume; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Mamoru Watanabe
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Clinical characteristics of null responders to Peg-IFNα2b/ribavirin therapy for chronic hepatitis C.

Authors:  Hideyuki Suzuki; Satoru Kakizaki; Norio Horiguchi; Takeshi Ichikawa; Ken Sato; Hitoshi Takagi; Masatomo Mori
Journal:  World J Hepatol       Date:  2010-11-27

4.  Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.

Authors:  Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yasuhiro Itsui; Seishin Azuma; Sei Kakinuma; Hiroshi Tanaka; Nobuyuki Enomoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

5.  Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.

Authors:  Mika Miura; Shinya Maekawa; Makoto Kadokura; Ryota Sueki; Kazuki Komase; Hiroko Shindo; Takako Ohmori; Asuka Kanayama; Kuniaki Shindo; Fumitake Amemiya; Yasuhiro Nakayama; Takatoshi Kitamura; Tomoyoshi Uetake; Taisuke Inoue; Minoru Sakamoto; Shunichi Okada; Nobuyuki Enomoto
Journal:  Hepatol Int       Date:  2011-08-17       Impact factor: 6.047

6.  Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Hirokazu Takahashi; Toshihiko Mizuta; Yuichiro Eguchi; Yasunori Kawaguchi; Takuya Kuwashiro; Satoshi Oeda; Hiroshi Isoda; Noriko Oza; Shinji Iwane; Kenichi Izumi; Keizou Anzai; Iwata Ozaki; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2011-02-18       Impact factor: 7.527

7.  Implication of protein kinase R gene quantification in hepatitis C virus genotype 4 induced hepatocarcinogenesis.

Authors:  Amal A Mohamed; Ola H Nada; Mohamed A El Desouky
Journal:  Diagn Pathol       Date:  2012-08-15       Impact factor: 2.644

8.  Association of hepatitis C virus with insulin resistance: evidences from animal studies and clinical studies.

Authors:  Sadaf Badar; Bushra Khubaib; Muhammad Idrees; Abrar Hussain; Zunaira Awan; Sadia Butt; Samia Afzal; Madeeha Akram; Zareen Fatima; Mahwish Aftab; Sana Saleem; Sara Munir; Bisma Rauff; Mahrukh Naudhani; Liaquat Ali; Muhammaad Ali; Irshadul Rehman
Journal:  Hepat Mon       Date:  2012-01-20       Impact factor: 0.660

9.  Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs.

Authors:  Stefania Paolucci; Antonio Piralla; Federica Novazzi; Alice Fratini; Renato Maserati; Roberto Gulminetti; Stefano Novati; Giorgio Barbarini; Paolo Sacchi; Annalisa De Silvestri; Fausto Baldanti
Journal:  Viruses       Date:  2020-02-25       Impact factor: 5.048

10.  Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy.

Authors:  K-C Chang; Y-Y Wu; C-H Hung; S-N Lu; C-M Lee; K-W Chiu; M-C Tsai; P-L Tseng; C-M Huang; C-L Cho; H-H Chen; T-H Hu
Journal:  Br J Cancer       Date:  2013-10-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.